Skip to main content
Premium Trial:

Request an Annual Quote

Bristol-Myers Promotes Head of Genomics Research to Senior Executive Post

NEW YORK, March 12 - Bristol-Myers Squibb has promoted its director of genomics-based pharmaceutical research, Elliot Sigal, to senior vice president in charge of drug discovery and exploratory development, the company said Monday.

The advancement for Sigal represents a "real sign of Elliot's leadership," said BMS spokeswoman Tracy Furey. "He is so highly regarded that he's now leading the whole discovery organization" at BMS' Pharmaceutical Research Institute, she said. 

Sigal joined BMS in 1997 as vice president for applied genomics, where he led the company's efforts to apply genomics to drug discovery. Prior to BMS, Sigal worked as CEO of Mercator Genetics, and earlier, as a faculty member in the department of medicine at the University of California, San Francisco.

Furey said the promotion did not indicate a greater shift in priorities towards genomics-based medicine, because "we have always made a significant investment in genomics." Instead, she said it was a major change for the company to place the entire research arm of the company under just one person.  
The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.